Tesamorelin
Egrifta
Tesamorelin is a growth hormone-releasing factor analog approved by the FDA as Egrifta for a narrow use: reducing excess abdominal fat in people with HIV-associated lipodystrophy. Uses outside that label have not been established by FDA review.
Key facts
- Commonly discussed for: reducing belly (visceral) fat.
- Evidence (B): Two phase 3 placebo-controlled trials (412 and 404 patients with HIV) showed visceral fat reductions of about 15% and 11% versus placebo over 26 weeks. Evidence for other uses is limited, so it is graded for a narrow approved indication.
- FDA status: FDA-approved. FDA approved Egrifta in November 2010 for reducing excess abdominal fat in HIV-infected patients with lipodystrophy.
- Legitimate access: Rx brand.
- Last reviewed: October 1, 2026.
Common questions
Is tesamorelin FDA approved?
Yes. FDA approved tesamorelin as Egrifta in November 2010 for one use: reducing excess abdominal (visceral) fat in adults with HIV-associated lipodystrophy. Any other use is off-label.
Is tesamorelin approved for fat loss in people without HIV?
No. The approval covers HIV-associated lipodystrophy only. Using it for general fat loss, body composition or anti-aging has not been reviewed or approved by FDA.
How do people get tesamorelin legally?
With a prescription from a licensed provider for the brand product, Egrifta. A prescriber can decide to use an approved drug off-label, but that is a medical decision, not an FDA-approved use.
Sources
- FDA approval letter, NDA 022505 Egrifta (tesamorelin for injection), 2010
- Falutz et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med, 2007
- Falutz et al. Effects of tesamorelin in HIV-infected patients with abdominal fat accumulation. J Acquir Immune Defic Syndr, 2010